We are a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of coronaviruses (including SARS-CoV-2), influenza viruses, noroviruses and hepatitis C viruses. We employ a unique structure-based drug discovery technology platform and Nobel Prize-winning expertise to create first- and best-in-class antiviral drugs.

We are leveraging our core competencies and decade of experience in antiviral therapeutics to combat the global COVID-19 health crisis. Given the growing global need for an effective, safe antiviral treatment, we are advancing multiple antiviral therapeutic candidates targeting SARS-CoV-2 as quickly and efficiently as possible, while also advancing the discovery and development of antiviral compounds for other high-value indications.

Nasdaq Bell Ringing Ceremony

Overview

Cocrystal Pharma Engages CRO to Conduct Phase 2a Human Challenge Influenza A Clinical Trial with Novel, Broad-Spectrum Antiviral Candidate CC-42344

Aug 8, 2022

Read Press Release

Q1 2022

Quarterly Results

Mar 31, 2022

PDF HTML

Release

PDF HTML

10-Q

HTML

Financials

ZIP XLS HTML

XBRL

Nasdaq:

COCP

Price

Change

Mkt Cap

Volume

52 week Low/High

Day Low/High

Cocrystal Pharma, Inc. Investor Presentation

Download

Cocrystal Pharma, Inc. is a clinical-stage biotechnology company seeking to discover and develop novel antiviral therapeutics as treatments for serious and/or chronic viral diseases. We employ unique structure-based technologies and Nobel Prize winning expertise to create first- and best-in-class antiviral drugs. These technologies are designed to efficiently deliver small molecule therapeutics that are safe, effective and convenient to administer. We have identified promising preclinical and early clinical stage antiviral therapeutics that target the replication process of influenza virus, SARS-CoV-2 virus, hepatitis C virus, and norovirus.

Sam Lee, Ph.D.

Interim Co-Chief Executive Officer and President

Dr. Sam Lee has over 25 years of anti-infective drug discovery research experience. Prior to Cocrystal, he managed anti-infective drug discovery projects for eight years at Icos Corporation (Nasdaq: ICOS). At Icos, Dr. Lee was… View Full Bio

James J. Martin

Interim Co-Chief Executive Officer and Chief Financial Officer

Mr. James Martin has over 25 years of finance and management experience including providing financial leadership to commercial-stage, publicly traded health science companies. Prior to Cocrystal, Mr. Martin served as the Chief Financial… View Full Bio

Roger Kornberg, Ph.D.

Chairman of the Board, Chief Scientist and Chairman of Scientific Advisory Board

Dr. Roger Kornberg is a member of the U.S. National Academy of Sciences and the Winzer Professor of Medicine in the Department of Structural Biology at Stanford University. He has been a member of the faculty of Stanford University since… View Full Bio

Steve Rubin

Vice Chairman

Mr. Steve Rubin is Executive Vice President-Administration and a director of OPKO Health, Inc. Previously, he was Senior Vice President and General Counsel of IVAX. Prior to IVAX, Mr. Rubin was Senior Vice President and General Counsel of… View Full Bio

Phillip Frost, M.D.

Director

Dr. Phillip Frost is the Chairman and CEO of OPKO Health, Inc. (NYSE: OPK). Dr. Frost is the former Chairman of the Board of Teva Pharmaceuticals (NYSE: TEVA). Dr. Frost served as Chairman and CEO of IVAX Corporation from 1987 through that… View Full Bio

Anthony Japour, M.D.

Director

Dr. Anthony Japour currently serves on the Boston Advisory Council for the George Washington School of Business Transformative Leadership during Disruptive Times Certificate Program. From May 2020 to August 2020, he served as CEO of… View Full Bio

Richard C. Pfenniger, Jr.

Director

Mr. Pfenniger is a private investor who served as Interim CEO of Vein Clinics of America, Inc., a privately held company that specializes in the treatment of vein disease, from May 2014 to February 2015, and as Interim CEO of IntegraMed… View Full Bio

Overview

Latest News

Latest Financial Results

Q1 2022

Stock Information

Nasdaq:

Price

Change

Mkt Cap

Volume

Company Overview

Officers & Directors

Sam Lee, Ph.D.

James J. Martin

Roger Kornberg, Ph.D.

Steve Rubin

Phillip Frost, M.D.

Anthony Japour, M.D.

Richard C. Pfenniger, Jr.

Overview

Latest News

Sign up for email alerts

Latest Financial Results

Q1 2022

Stock Information

Nasdaq:

Price

Change

Mkt Cap

Volume

Company Overview

Officers & Directors

Sam Lee, Ph.D.

James J. Martin

Roger Kornberg, Ph.D.

Steve Rubin

Phillip Frost, M.D.

Anthony Japour, M.D.

Richard C. Pfenniger, Jr.